Claus Bolling

1.4k total citations · 1 hit paper
32 papers, 593 citations indexed

About

Claus Bolling is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Claus Bolling has authored 32 papers receiving a total of 593 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 15 papers in Gastroenterology. Recurrent topics in Claus Bolling's work include Gastric Cancer Management and Outcomes (19 papers), Gastrointestinal Tumor Research and Treatment (15 papers) and Colorectal Cancer Treatments and Studies (11 papers). Claus Bolling is often cited by papers focused on Gastric Cancer Management and Outcomes (19 papers), Gastrointestinal Tumor Research and Treatment (15 papers) and Colorectal Cancer Treatments and Studies (11 papers). Claus Bolling collaborates with scholars based in Germany, Switzerland and United States. Claus Bolling's co-authors include Christian Brandts, Gerhard Rogler, Peter Higgins, Daan Dierickx, Rami Eliakim, Livia Biancone, Konstantinos H. Katsanos, Loes H.C. Nissen, Laurence J. Egan and Edyta Szymańska and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Claus Bolling

30 papers receiving 588 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies

2015 284 citations Vito Annese, Laurent Beaugerie et al. Journal of Crohn s and Colitis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claus Bolling Germany	9	234	208	207	204	163	32	593
George Kouklakis Greece	13	175 0.7×	73 0.4×	236 1.1×	158 0.8×	80 0.5×	28	537
S. A. C. Dundas United Kingdom	13	194 0.8×	198 1.0×	234 1.1×	114 0.6×	183 1.1×	19	659
Dev Segarajasingam Australia	8	278 1.2×	61 0.3×	329 1.6×	175 0.9×	110 0.7×	15	600
Adam Dangoor United Kingdom	11	284 1.2×	44 0.2×	117 0.6×	435 2.1×	43 0.3×	23	667
Valentina Fausti Italy	16	321 1.4×	54 0.3×	74 0.4×	260 1.3×	134 0.8×	46	681
P Blok Netherlands	21	207 0.9×	258 1.2×	758 3.7×	521 2.6×	202 1.2×	40	1.2k
Kjell E. Kjørstad Norway	19	275 1.2×	78 0.4×	230 1.1×	119 0.6×	458 2.8×	34	1.2k
Juan C. Tardío Spain	15	211 0.9×	53 0.3×	126 0.6×	279 1.4×	122 0.7×	56	679
H Steininger Germany	18	208 0.9×	94 0.5×	432 2.1×	110 0.5×	51 0.3×	37	887
Masanori Aramaki Japan	16	527 2.3×	66 0.3×	587 2.8×	364 1.8×	154 0.9×	53	939

Countries citing papers authored by Claus Bolling

Since Specialization

Citations

This map shows the geographic impact of Claus Bolling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claus Bolling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claus Bolling more than expected).

Fields of papers citing papers by Claus Bolling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claus Bolling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claus Bolling. The network helps show where Claus Bolling may publish in the future.

Co-authorship network of co-authors of Claus Bolling

This figure shows the co-authorship network connecting the top 25 collaborators of Claus Bolling. A scholar is included among the top collaborators of Claus Bolling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claus Bolling. Claus Bolling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Moying, Nadja M. Meindl‐Beinker, Johannes Betge, et al.. (2024). Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study. Journal of Geriatric Oncology. 15(7). 101838–101838.

Al‐Batran, Salah‐Eddin, Sylvie Lorenzen, Jorge Riera, et al.. (2024). Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial.. Journal of Clinical Oncology. 42(17_suppl). LBA4001–LBA4001. 13 indexed citations

Goetze, Thorsten Oliver, Alexander Reichart, Claudia Pauligk, et al.. (2024). Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial. Annals of Surgical Oncology. 31(6). 4073–4083. 2 indexed citations

Lorenzen, Sylvie, Thorsten Oliver Goetze, Peter Thuss‐Patience, et al.. (2024). LBA59 Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial. Annals of Oncology. 35. S1249–S1250. 2 indexed citations

Lorenzen, Sylvie, Peter Thuss‐Patience, Jorge Riera Knorrenschild, et al.. (2022). 1203O FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO. Annals of Oncology. 33. S1099–S1099. 2 indexed citations

Al-Batran, Salah-Eddin, Sylvie Lorenzen, Peter Thuss‐Patience, et al.. (2022). Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.. Journal of Clinical Oncology. 40(16_suppl). 4003–4003. 70 indexed citations

Lorenzen, Sylvie, Peter Thuss‐Patience, Jorge Riera Knorrenschild, et al.. (2022). FOLFOX versus FOLFOX plus nivolumab and ipilimumab administered in parallel or sequentially versus FLOT plus nivolumab administered in parallel in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase 2 trial of the AIO.. Journal of Clinical Oncology. 40(16_suppl). 4043–4043. 2 indexed citations

Al-Batran, S-E., Sylvie Lorenzen, Nils Homann, et al.. (2021). 1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK. Annals of Oncology. 32. S1069–S1069. 22 indexed citations

Kopp, Christina, Sylvie Lorenzen, Timo Gaiser, et al.. (2021). 1430P Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: Perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. A randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK. Annals of Oncology. 32. S1069–S1070. 2 indexed citations

10.

Pauligk, Claudia, Peter Thuss‐Patience, Jorge Riera‐Knorrenschild, et al.. (2020). 1443P Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO. Annals of Oncology. 31. S908–S908. 6 indexed citations

11.

Al-Batran, S-E., Sylvie Lorenzen, Peter Thuss‐Patience, et al.. (2020). 1494P Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma - A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK. Annals of Oncology. 31. S927–S928. 5 indexed citations

12.

Al‐Batran, Salah‐Eddin, Sylvie Lorenzen, Michael Schenk, et al.. (2020). Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK.. Journal of Clinical Oncology. 38(4_suppl). 398–398. 4 indexed citations

13.

Al-Batran, S-E., Claudia Pauligk, Ralf‐Dieter Hofheinz, et al.. (2019). Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK. Annals of Oncology. 30. v324–v324. 4 indexed citations

14.

Bolling, Claus, Lutz Vogt, Daniel Niederer, et al.. (2018). Exercise improves functional capacity and lean body mass in patients with gastrointestinal cancer during chemotherapy: a single-blind RCT. Supportive Care in Cancer. 27(6). 2159–2169. 33 indexed citations

15.

Schmalenberg, Harald, Salah‐Eddin Al‐Batran, Claudia Pauligk, et al.. (2017). CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach. Journal of Cancer Research and Clinical Oncology. 144(3). 559–569. 5 indexed citations

16.

Bolling, Claus, et al.. (2016). P-208 Pre-therapy physical function and body status of patients with advanced gastrointestinal cancer compared to breast cancer patients and healthy women. Annals of Oncology. 27. ii60–ii60. 1 indexed citations

17.

Annese, Vito, Laurent Beaugerie, Laurence J. Egan, et al.. (2015). European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. Journal of Crohn s and Colitis. 9(11). 945–965. 284 indexed citations breakdown →

18.

Hanauske, Axel‐R., Jim Cassidy, Javier Sastre, et al.. (2007). Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research. 13(2). 523–531. 19 indexed citations

19.

Bolling, Claus, Feliksas Jankevičius, Alvydas Česas, et al.. (2006). Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Investigational New Drugs. 24(6). 521–527. 58 indexed citations

20.

Bolling, Claus, et al.. (2004). Pemetrexed/gemcitabine/cisplatin: Phase I trial in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3096–3096. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact